2 recruiting, 1 active not recruiting, 1 withdrawn. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Withdrawn 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow HR-positive Breast Cancer: new trials by email Literature Review of HR-positive Breast Cancer trials Research Report on HR-positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment Capivasertib - Breast Cancer, HR-positive Breast Cancer | Phase 3 | Recruiting | Women's Cancer Study Group GmbH | 250 | 2025-11-27 | 2026-08-05 |
| Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study Palbociclib, Ribociclib, Abemaciclib - Breast Adenocarcinoma, Breast Cancer Stage IV | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 3500 | 2023-05-01 | 2025-02-03 | |
| Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer Vitamin B12, Blood collection, Brief Pain Inventory - Short Form survey - HR-positive Breast Cancer | Not applicable | Withdrawn | Case Comprehensive Cancer Center | 2021-08-12 | 2024-08-21 | |
| Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Pembrolizumab, Sacituzumab Govitecan - Invasive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Active not recruiting | Ana C Garrido-Castro, MD | 110 | 2020-09-23 | 2026-01-15 |
Breast Neoplasms (3) · Neoplasm Metastasis (2) · Breast Diseases (1) · Breast Neoplasms, Male (1) · Disease Progression (1)
Neoplasms (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Breast Diseases (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1)
Blood Specimen Collection (1) · Vitamin B 12 (1) · abemaciclib (1) · capivasertib (1) · palbociclib (1) · pembrolizumab (1) · ribociclib (1) · sacituzumab govitecan (1)
Ana C Garrido-Castro, MD (1) · Case Comprehensive Cancer Center (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Women's Cancer Study Group GmbH (1)
United States (2) · Belgium (1) · Germany (1) · Italy (1) · Portugal (1)
Ana Garrido-Castro, MD (1) · Peter Schmid, PHD Dr (1) · Zeina Nahleh, MD (1)